In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4712-4717

  Vidaillac, Céline ^a   Leonard, Steve N ^a,c,d   Rybak, Michael J ^a,b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG HALF LIFE; DRUG RESISTANCE; DRUG STABILITY; DRUG TOLERANCE; HOLLOW FIBER; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 70350326281     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00636-09     Document Type: Article

References (31)

1. Allen, G. P., G. W. Kaatz, and M. J. Rybak. 2004. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. Int. J. Antimicrob. Agents 24:150-160.
2. Clinical and Laboratory Standards Institute. 2008. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 8th ed. CLSI, Wayne, PA.
3. Corey, G. R., M. Wilcox, G. H. Talbot, T. Baculik, and D. Thye. 2008. CANVAS-1: randomized, double-blinded, phase 3 study (P903-06) of the efficacy and safety of ceftaroline vs. vancomycin plus aztreonam in complicated skin and skin structure infections (cSSSI), abstr. L-1515a, p. 321. Final Program Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
4. Drusano, G. L., W. Liu, D. L. Brown, L. B. Rice, and A. Louie. 2009. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J. Infect. Dis. 199:219-226.
5. Ge, Y., D. Biek, G. H. Talbot, and D. F. Sahm. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407.
6. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
7. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
8. Iizawa, Y., J. Nagai, T. Ishikawa, S. Hashiguchi, M. Nakao, A. Miyake, and K. Okonogi. 2004. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599. J. Infect. Chemother. 10:146-156.
9. Jacqueline, C., J. Caillon, V. Le Mabecque, A. F. Miègeville, A. Hamel, D. Bugnon, J. Y. Ge, and G. Potel. 2007. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob. Agents Chemother. 51:3397-3400.
10. Jones, R. N. 2008. Key considerations in the treatment of complicated staphylococcal infections. Clin. Microbiol. Infect. 14(Suppl. 2):3-9.
11. Kluytmans, J., and M. Struelens. 2009. Meticillin resistant Staphylococcus aureus in the hospital. BMJ 338:b364.
12. Leonard, S. N., C. Vidaillac, and M. J. Rybak. 2009. Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 53:2928-2933.
13. Levine, D. P. 2008. Vancomycin: understanding its past and preserving its future. South. Med. J. 101:284-291.
14. Lodise, T. P., Jr., R. Pypstra, J. B. Kahn, B. P. Murthy, H. C. Kimko, K. Bush, G. J. Noel, and G. L. Drusano. 2007. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob. Agents Chemother. 51:2378-2387.
15. Maor, Y., M. Hagin, N. Belausov, N. Keller, D. Ben-David, and G. Rahav. 2009. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J. Infect. Dis. 199:619-624.
16. Matzke, G. R., G. G. Zhanel, and D. R. Guay. 1986. Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet. 11:257-282.
17. Mendes, R. E., L. M. Deshpande, M. Castanheira, J. DiPersio, M. A. Saubolle, and R. N. Jones. 2008. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob. Agents Chemother. 52:2244-2246.
18. Mushtaq, S., M. Warner, Y. Ge, K. Kaniga, and D. M. Livermore. 2007. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J. Antimicrob. Chemother. 60:300-311.
19. Page, M. G. 2006. Anti-MRSA beta-lactams in development. Curr. Opin. Pharmacol. 6:480-485.
20. Parish, D., and N. Scheinfeld. 2008. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr. Opin. Investig. Drugs 9:201-209.
21. Ratnaraja, N. V., and P. M. Hawkey. 2008. Current challenges in treating MRSA: what are the options? Expert Rev. Anti Infect. Ther. 6:601-618.
22. Riccobene, T., E. Fang, and D. Thye. 2008. A single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects, abstr. A-1888, p. 34. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
23. Rybak, M. J. 2004. Resistance to antimicrobial agents: an update. Pharmacotherapy 24:203S-215S.
24. Sadaba, B., J. R. Azanza, M. A. Campanero, and E. Garcia-Quetglas. 2004. Relationship between pharmacokinetics and pharmacodynamics of betalactams and outcome. Clin. Microbiol. Infect. 10:990-998.
25. Stapleton, P. D., and P. W. Taylor. 2002. Methicillin resistance in Staphylococcus aureus: mechanisms and modulation. Sci. Prog. 85:57-72.
26. Talbot, G. H., D. Thye, A. Das, and Y. Ge. 2007. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51:3612-3616.
27. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.
28. Vidaillac, C., S. N. Leonard, and M. J. Rybak. 2008. In vitro activity and aminoglycoside synergy of ceftaroline against clinical isolates of hospital-acquired (HA) methicillin-resistant Staphylococcus aureus (MRSA), abstr. C1-3719, p. 134. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
29. Vidaillac, C., S. N. Leonard, and M. J. Rybak. 2008. In vitro activity of ceftaroline (CPT) vs. vancomycin (VM) against MRSA and hVISA strains in a pharmacokinetic/pharmacodynamic (PK/PD) model, abstr. A-979, p. 21. Abstr. 48th Annu. Intersci. Conf. Antimicrob. Agents Chemother. (ICAAC)-Infect. Dis. Soc. Am. (IDSA) 46th Annu. Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC.
30. Wilson, P., J. A. Andrews, R. Charlesworth, R. Walesby, M. Singer, D. J. Farrell, and M. Robbins. 2003. Linezolid resistance in clinical isolates of Staphylococcus aureus. J. Antimicrob. Chemother. 51:186-188.
31. Wootton, M., R. A. Howe, R. Hillman, T. R. Walsh, P. M. Bennett, and A. P. MacGowan. 2001. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J. Antimicrob. Chemother. 47:399-403.